Quotes: US MENA   Enter Symbol: NewsLetter: Search: advanced

Server is busy please try again later.  Join our daily free Newsletter

MENAFN Press - 17/10/2012
No. of Ratings : 0
Add to Mixx!



Due to technical reasons, this story has been removed from our database.

About CytoDyn Inc
CytoDyn is a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses and other antibody applications. Its proprietary drug candidate Cytolin(R) is a monoclonal antibody that binds to CD11a, a cellular antigen that is a component of the cellular adhesion molecule LFA-1. CytoDyn intends to explore the clinical development of Cytolin(R) for persons infected with the Human Immunodeficiency Virus ('HIV") to determine if it could perturb the natural course of HIV infection. CytoDyn recently completed a humanized antibody construct of Cytolin(R), filed a provisional patent for its use, and manufacturing discussions are underway. In addition, CytoDyn is exploring the possible application of its existing proprietary monoclonal antibody for the treatment of Feline Immunodeficiency Virus ("FIV"), a retroviral infection in cats. CytoDyn recently filed for a provisional patent for the use of these antibodies as well as selected small molecule antagonists and agonists for the treatment of FIV, and filed an application for registration of the trademark CytoFeline, intended for use in conjunction with veterinary preparations for the treatment of FIV. For more information about Cytolin(R), CytoFeline(TM) and CytoDyn please go to www.cytodyn.com.Forward-Looking StatementsThis press release includes forward-looking statements and forward-looking information within the meaning of United States securities laws. These statements and information represent CytoDyn's intentions, plans, expectations and beliefs, and are subject to risks, uncertainties and other factors, of which many are beyond CytoDyn's control. These factors could cause actual results to differ materially from such forward-looking statements or information. The words "believe," "estimate," "expect," "intend," "attempt," "anticipate," "foresee," "plan," and similar expressions and variations thereof, identify certain of such forward-looking statements or forward-looking information, which speak only as of the date on which they are made. CytoDyn disclaims any intention or obligation to publicly update or revise any forward-looking statements or forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned not to place undue reliance on these forward-looking statements or forward-looking information.While it is impossible to identify or predict all such matters, these differences may result from, among other things, the inherent uncertainty of the timing and success of, and expense associated with, research, development, regulatory approval and commercialization of our products and product candidates, including the risks that clinical trials will not commence or proceed as planned; products appearing promising in early trials will not demonstrate efficacy or safety in larger-scale trials; future clinical trial data on our products and product candidates will be unfavorable; our products will not receive marketing approval from regulators or, if approved, fail to gain sufficient market acceptance to justify development and commercialization costs; competing products currently on the market or in development may reduce the commercial potential of our products; CytoDyn, our collaborators or others may identify side effects after the product is on the market; or efficacy or safety concerns regarding marketed products, whether or not scientifically justified, may lead to product recalls, withdrawals of marketing approval, reformulation of the product, additional pre-clinical testing or clinical trials, changes in labeling of the product, the need for additional marketing applications, or other adverse events.We are also subject to additional risks and uncertainties, including risks associated with the actions of our corporate, academic and other collaborators and government regulatory agencies; risks from market forces and trends; potential product liability; intellectual property, litigation, environmental and other risks; and risks that current and pending patent protection for our products may be invalid, unenforceable or challenged, or fail to provide adequate market exclusivity. There are also substantial risks arising out of our need to raise additional capital to develop our products and satisfy our financial obligations; the highly regulated nature of our business, including government cost-containment initiatives and restrictions on third-party payments for our products; the highly competitive nature of our industry; and other factors set forth in our Annual Report on Form 10-K and other reports filed with the U.S. Securities and Exchange Commission.

 


MENAFN Press




  MENA News Headlines
 Oct 22 2014 - China Fiscal Revenue Rises 6.3% in SeptemberQatar News Agency
(MENAFN - QNA) China's fiscal revenue rose 6.3% year on year to 995.3 billion yuan about (162.6 billion US dollars) in September, quickening from a 6.1% rise in August, the Chinese Ministry of ...

 Oct 22 2014 - Tokyo Stocks End Sharply up WednesdayQatar News Agency
(MENAFN - QNA) Tokyo stocks ended sharply higher Wednesday, boosted by overnight rises in European and US stocks. The 225-issue Nikkei Stock Average rose 391.49 points, or 2.64%, from Tuesday to ...

 Oct 22 2014 - Cooperating Robots Developed in China-US ProjectQatar News Agency
(MENAFN - QNA) An award-winning collaboration between Chinese and American researchers has pointed the way forward for the use of cloud computing to link different robots and make them more ...

 Oct 22 2014 - Summary of Local News Released Tuesday - 3-Qatar News Agency
(MENAFN - QNA) - World Innovation Summit for Health (WISH) has appointed chairperson for the WISH Dementia Forum that will mull current challenges, innovation in care-giving, financial models and ...

 Oct 22 2014 - Ban Calls for Investigation into Israeli Attacks on UN Facilities in GazaQatar News Agency
(MENAFN - QNA) United Nations Secretary-General Ban Ki-moon called for a thorough investigation into incidents where UN facilities sustained hits and many innocent people were killed by the Israeli ...

 Oct 22 2014 - China Responds over "Hacker Infiltration to Apple's iCloud"Qatar News Agency
(MENAFN - QNA) China reiterated opposition to cyber attacks from hackers in all forms after media reported Chinese hackers infiltrated Apple's iCloud. "China is resolutely opposed to hacker attacks ...

 Oct 22 2014 - At Least 37 Taliban Militants Killed in AfghanistanQatar News Agency
(MENAFN - QNA) At least 37 Taliban militants were killed following military operations by Afghan national security forces in the past 24. The Afghan Ministry of Interior said Wednesday that the ...

 Oct 22 2014 - Japan's KEPCO to Submit Revised Takahama Safety PlanQatar News Agency
(MENAFN - QNA) The operator of a power plant on the Sea of Japan coast says it will submit revised safety measures to the country's nuclear regulator as early as next week, Japan's (NHK World) ...

 Oct 22 2014 - OIC states condemn Israeli violations against Al-Aqsa Mosque and Muslim worshipers 3 New YorkSaudi Press Agency
(MENAFN - Saudi Press Agency)  On Syria, the ambassador expressed deep concern about the escalation of acts of destruction, violence, murder and heinous crimes committed against the Syrian people as ...

 Oct 22 2014 - Saudi Transport Minister heads Kingdom's delegation to meetings of Arab Transport Ministers in EgyptSaudi Press Agency
(MENAFN - Saudi Press Agency)  The Council of Arab Ministers of Transport started their 27th session here today in the presence of Ministers of Transport and Communications of various Arab ...

more...


 






Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country

IPO News
Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

US Markets Details

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Investment Game
Economic Calendar
Financial Glossary

My MENAFN
Portfolio Tracker

Voting

Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2000 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help